Mitoxantrone
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Institut de Recherches Internationales Servier
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02632708CT.gov Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | — | Active Not Recruiting | — | — | — |
NCT02583893CT.gov Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02299518CT.gov Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02044796CT.gov Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT01801046CT.gov Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01839240CT.gov Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01349972CT.gov Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01260714CT.gov Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01174888CT.gov Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00795002CT.gov Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00407966CT.gov Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00016016CT.gov Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mitoxantrone (this asset) | Institut de Recherches Internationales Servier | P2 | BB · 68 |
| Nivestim | City of Hope Medical Center | P2/3 | BBB |
| Cytarabine | National Cancer Institute (NCI) | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Idarubicin | Fred Hutchinson Cancer Center | P2/3 | BB |
| Etoposide | M.D. Anderson Cancer Center | P3 | BB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BB |
| Melphalan | City of Hope Medical Center | P2 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort
Other indications for Mitoxantrone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | BBB · 77 |
| Acute Monocytic Leukemia | — | P2/3 | BBB · 74 |
| Myeloid Neoplasm | — | P3 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Mitoxantrone in Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/mitoxantrone-therapy-related-acute-myeloid-leukemia-and-myelodysplastic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →